KG&L Capital Management LLC Has $679,000 Stake in GSK plc (NYSE:GSK)

KG&L Capital Management LLC raised its stake in GSK plc (NYSE:GSK) by 44.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 16,685 shares of the pharmaceutical company’s stock after buying an additional 5,104 shares during the quarter. KG&L Capital Management LLC’s holdings in GSK were worth $679,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently added to or reduced their stakes in GSK. Primecap Management Co. CA lifted its stake in GSK by 13.9% in the second quarter. Primecap Management Co. CA now owns 14,511,390 shares of the pharmaceutical company’s stock valued at $558,689,000 after buying an additional 1,773,020 shares during the period. Mondrian Investment Partners LTD increased its holdings in shares of GSK by 37.8% in the first quarter. Mondrian Investment Partners LTD now owns 5,510,840 shares of the pharmaceutical company’s stock worth $236,250,000 after acquiring an additional 1,512,442 shares in the last quarter. Acadian Asset Management LLC increased its holdings in shares of GSK by 180.0% in the first quarter. Acadian Asset Management LLC now owns 2,219,798 shares of the pharmaceutical company’s stock worth $95,129,000 after acquiring an additional 1,426,935 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund bought a new stake in shares of GSK in the second quarter worth about $52,487,000. Finally, Kahn Brothers Group Inc. bought a new stake in shares of GSK in the first quarter worth about $53,743,000. Institutional investors and hedge funds own 15.74% of the company’s stock.

GSK Stock Up 0.3 %

NYSE:GSK opened at $36.88 on Monday. The company has a debt-to-equity ratio of 0.98, a quick ratio of 0.54 and a current ratio of 0.81. The company has a market cap of $76.44 billion, a PE ratio of 23.95, a PEG ratio of 1.45 and a beta of 0.66. GSK plc has a 52-week low of $33.67 and a 52-week high of $45.92. The stock has a 50-day simple moving average of $40.66 and a 200 day simple moving average of $41.04.

GSK Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, January 9th. Shareholders of record on Friday, November 15th will be paid a $0.3928 dividend. This represents a $1.57 dividend on an annualized basis and a yield of 4.26%. This is an increase from GSK’s previous quarterly dividend of $0.38. The ex-dividend date of this dividend is Friday, November 15th. GSK’s dividend payout ratio (DPR) is currently 100.00%.

Analyst Ratings Changes

GSK has been the subject of several recent analyst reports. Barclays upgraded GSK to a “hold” rating in a report on Tuesday, August 27th. Argus upgraded GSK to a “strong-buy” rating in a report on Wednesday, August 7th. Guggenheim downgraded GSK from a “buy” rating to a “neutral” rating in a report on Thursday. Finally, UBS Group downgraded GSK from a “buy” rating to a “neutral” rating in a report on Monday, July 8th. Five equities research analysts have rated the stock with a hold rating, one has given a buy rating and three have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $50.00.

Insider Buying and Selling at GSK

In related news, major shareholder Plc Gsk purchased 2,791,930 shares of the firm’s stock in a transaction on Friday, September 27th. The stock was purchased at an average cost of $8.00 per share, for a total transaction of $22,335,440.00. Following the completion of the purchase, the insider now directly owns 16,775,691 shares in the company, valued at $134,205,528. This trade represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 10.00% of the company’s stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.